Literature DB >> 9652134

The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases.

Y Reisner1, S Dagan.   

Abstract

Monoclonal antibodies of human origin may have great therapeutic value in the treatment of cancer, autoimmune disorders and viral or bacterial infections. Several methods for generating human monoclonal antibodies exist; some are based on the transplantation of a functioning human immune system into severe combined immunodeficient (scid) mice or into Trimera mice, which are mice that have been lethally irradiated and radioprotected by transplantation of bone-marrow cells from scid mice. Trimera mice could be also used to develop animal models for human diseases by transplanting infected human tissue fragments and for creating models for cell therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652134     DOI: 10.1016/s0167-7799(98)01203-7

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  8 in total

1.  Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.

Authors:  C Gysemans; M Waer; J Laureys; J Depovere; D Pipeleers; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo.

Authors:  W O Böcher; H Marcus; R Shakarchy; B Dekel; D Shouval; E Galun; Y Reisner
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 3.  Hepatitis C virus experimental model systems and antiviral drug research.

Authors:  Susan L Uprichard
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

4.  Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens.

Authors:  Nicolas Brezillon; Dina Kremsdorf; Mary C Weiss
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

5.  Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras.

Authors:  Zev Sthoeger; Heidy Zinger; Benny Dekel; Fabian Arditi; Yair Reisner; Edna Mozes
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

6.  Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display library.

Authors:  Sonia Schoonbroodt; Nicolas Frans; Mark DeSouza; Rachel Eren; Smadar Priel; Naama Brosh; Judith Ben-Porath; Arie Zauberman; Ehud Ilan; Shlomo Dagan; Edward H Cohen; Hennie R Hoogenboom; Robert Charles Ladner; René M Hoet
Journal:  Nucleic Acids Res       Date:  2005-05-19       Impact factor: 16.971

Review 7.  Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.

Authors:  James A Heslop; Thomas G Hammond; Ilaria Santeramo; Agnès Tort Piella; Isabel Hopp; Jing Zhou; Roua Baty; Enrique I Graziano; Bernabé Proto Marco; Alexis Caron; Patrik Sköld; Peter W Andrews; Melissa A Baxter; David C Hay; Junnat Hamdam; Michaela E Sharpe; Sara Patel; David R Jones; Jens Reinhardt; Erik H J Danen; Uri Ben-David; Glyn Stacey; Petter Björquist; Jacqueline Piner; John Mills; Cliff Rowe; Giovanni Pellegrini; Swaminathan Sethu; Daniel J Antoine; Michael J Cross; Patricia Murray; Dominic P Williams; Neil R Kitteringham; Chris E P Goldring; B Kevin Park
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

Review 8.  Therapeutic applications of monoclonal antibodies.

Authors:  Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal:  Am J Med Sci       Date:  2002-07       Impact factor: 2.378

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.